Plus Therapeutics And SpectronRx Collaboration Fuels Radiotherapy For CNS Cancers

Plus Therapeutics, Inc., a pharmaceutical company focused on developing targeted radiotherapies for cancers of the central nervous system (CNS), has entered into a Manufacturing Services Agreement (MSA) with SpectronRx, leading in radiopharmaceutical contract-based development and manufacturing. This collaboration focuses on producing Rhenium (186Re) Obisbemeda, a radiotherapy for treating CNS cancers, including leptomeningeal metastases and recurrent glioblastoma.

Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer, said in a statement, “In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial-level product demand. Therefore, now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as SpectronRx, which can deliver for us and our patients. We believe that SpectronRx’s capabilities will significantly reinforce our existing manufacturing partnerships and position us well for the long term.”

This agreement enables SpectronRx to use its best-in-class facilities to make clinical and commercial Rhenium (186Re) Obisbemeda supplies. SpectronRx operates over 170,000 square feet of radiopharmaceutical contract development and manufacturing space and employs 150 people across five different locations. At present, it serves 29 countries and is engaged with more than 31 pharmaceutical companies in developing as well as producing life-saving nuclear medicines that include radiolabeled with 186Re. This partnership with Plus Therapeutics enables SpectronRx to focus on advancing atomic medicine. 

“We are proud to align with Plus Therapeutics, leveraging our expertise in nuclear medicine manufacturing to support the advancement of Rhenium (186Re) Obisbemeda and increase patient access to this important therapy. This collaboration underscores our dedication to advancing nuclear medicine and providing patients with high-quality, life-saving radiotherapies. We look forward to supporting Plus Therapeutics' mission to address the unmet needs of CNS cancer patients,” commented Anwer Rizvi, President of SpectronRx.

This collaboration strengthens Plus Therapeutics' supply chain and ensures its readiness to meet the demand of advanced clinical trials and potential commercial scaling. The agreement signifies a key milestone in making Rhenium (186Re) Obisbemeda more widely accessible to needy patients.